---
title: "BeOne Medicines Earnings Report: Q4 Overview"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277027138.md"
description: "BeOne Medicines (NASDAQ:ONC) reported its Q4 earnings on February 26, 2026, beating estimates by 37.32% with an EPS of $1.95 compared to the expected $1.42. Revenue increased by $370 million year-over-year. In the previous quarter, the company also exceeded EPS estimates by $1.85, but shares dropped 3.73% the following day. Historical performance shows consistent revenue growth, with actual revenues surpassing estimates in recent quarters."
datetime: "2026-02-26T11:02:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277027138.md)
  - [en](https://longbridge.com/en/news/277027138.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277027138.md)
---

# BeOne Medicines Earnings Report: Q4 Overview

**BeOne Medicines** (NASDAQ:ONC) released its Q4 earnings on Thursday, February 26, 2026 at 06:00 AM.

Here's what's important from the earnings announcement.

### Earnings

BeOne Medicines beat estimated earnings by 37.32%, reporting an EPS of $1.95 versus an estimate of $1.42.

Revenue was up $370.00 million from the same period last year.

### Earnings History Overview

The company beat on EPS by $1.85 in the last quarter, resulting in a 3.73% drop share price change the following day.

Here's a look at BeOne Medicines's past performance:

**Quarter**

**Q3 2025**

**Q2 2025**

**Q1 2025**

**Q4 2024**

**EPS Estimate**

0.80

0.35

\-0.74

\-1.02

**EPS Actual**

2.65

2.25

1.22

\-1.43

**Revenue Estimate**

1.35B

1.24B

1.14B

1.04B

**Revenue Actual**

1.41B

1.32B

1.12B

1.13B

To track all earnings releases for BeOne Medicines visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BPMC.US](https://longbridge.com/en/quote/BPMC.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)

## Related News & Research

- [BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative](https://longbridge.com/en/news/287245995.md)
- [BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts | ONC Stock News](https://longbridge.com/en/news/287198763.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)
- [BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer](https://longbridge.com/en/news/286453582.md)
- [BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma | ONC Stock News](https://longbridge.com/en/news/286297796.md)